DiaMedica Therapeutics Inc.
Clinical-stage biopharma developing therapies for ischemic and vascular diseases.
DMAC | US
Overview
Corporate Details
- ISIN(s):
- CA25253X2077
- LEI:
- Country:
- United States of America
- Address:
- 301 CARLSON PARKWAY, 55305 MINNEAPOLIS
- Website:
- https://www.diamedica.com/
- Sector:
- Manufacturing
Description
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for serious ischemic and vascular diseases with significant unmet medical needs. The company's lead drug candidate is DM199, a recombinant form of the human tissue kallikrein-1 (rhKLK1) protein. DM199 is designed to restore vascular health and function through a novel mechanism of action, aiming to improve patient outcomes by reversing the effects of ischemic injury. The development programs are primarily focused on treating acute ischemic stroke (AIS), preeclampsia (PE), and fetal growth restriction (FGR), conditions for which there are currently limited or no approved therapies available to address the underlying disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all DiaMedica Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DiaMedica Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DiaMedica Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
